104 results on '"Qin, Yan‐ru"'
Search Results
2. A multicenter clinical study: personalized medication for advanced gastrointestinal carcinomas with the guidance of patient-derived tumor xenograft (PDTX)
- Author
-
Cheng, Yuan, Qin, Shu-kui, Li, Jin, Dai, Guang-hai, Shen, Bai-yong, Ying, Jie-er, Ba, Yi, Liang, Han, Wang, Xin-bo, Xu, Ye, Zhou, Lin, Ding, Ke-feng, Qin, Yan-ru, Yang, Shu-jun, Guan, Wen-xian, Zheng, Hui, Wang, Qian, Song, Hang, and Zhu, Yan-ping
- Published
- 2022
- Full Text
- View/download PDF
3. Identification and characterization of FGFR2+ hematopoietic stem cell-derived fibrocytes as precursors of cancer-associated fibroblasts induced by esophageal squamous cell carcinoma
- Author
-
Qiu, Haibo, Zhang, Xu, Qi, Jiali, Zhang, Jiangwen, Tong, Yin, Li, Lei, Fu, Li, Qin, Yan-Ru, Guan, Xinyuan, and Zhang, Liyi
- Published
- 2022
- Full Text
- View/download PDF
4. Genome-wide identification of key regulatory lncRNAs in esophageal cancer metastasis
- Author
-
Xu, Wen Wen, Zheng, Can-Can, Zuo, Qian, Li, Jun-Qi, Hong, Pan, Qin, Yan-Ru, Guan, Xin-Yuan, He, Qing-Yu, Liao, Hua-Xin, and Li, Bin
- Published
- 2021
- Full Text
- View/download PDF
5. RNA editing of SLC22A3 drives early tumor invasion and metastasis in familial esophageal cancer
- Author
-
Fu, Li, Qin, Yan-Ru, Ming, Xiao-Yan, Zuo, Xian-Bo, Diao, Yu-Wen, Zhang, Li-Yi, Ai, Jiaoyu, Liu, Bei-Lei, Huang, Tu-Xiong, Cao, Ting-Ting, Tan, Bin-Bin, Xiang, Di, Zeng, Chui-Mian, Gong, Jing, Zhang, Qiangfeng, Dong, Sui-Sui, Chen, Juan, Liu, Haibo, Wu, Jian-Lin, Qi, Robert Z., Xie, Dan, Wang, Li-Dong, and Guan, Xin-Yuan
- Published
- 2017
6. Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
- Author
-
Chang, Zhiwei, Liu, Xiao-Lei, Yu, Dan-Dan, Han, Hui-Qiong, He, Jian, Wang, Rui-Rui, and Qin, Yan-ru
- Published
- 2024
- Full Text
- View/download PDF
7. The genomic landscape of small cell carcinoma of the esophagus
- Author
-
Wang, Feng, Liu, Dong-Bing, Zhao, Qi, Chen, Gang, Liu, Xin-Ming, Wang, Ying-Nan, Su, Hong, Qin, Yan-Ru, He, Yi-Fu, Zou, Qing-Feng, Liu, Yan-Hui, Lin, You-En, Liu, Ze-Xian, Bei, Jin-Xin, and Xu, Rui-Hua
- Published
- 2018
- Full Text
- View/download PDF
8. LncRNA-TUSC7/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESC1
- Author
-
Chang, Zhi-wei, Jia, Yong-xu, Zhang, Wei-jie, Song, Li-jie, Gao, Ming, Li, Ming-jun, Zhao, Rui-hua, Li, Jing, Zhong, Ya-li, Sun, Qiao-zhi, and Qin, Yan-ru
- Published
- 2018
- Full Text
- View/download PDF
9. Health‐related quality of life in stage III‐IV melanoma treated with targeted therapy or immunotherapy: A systematic review on the adequacy of reporting and clinical issues in phase III randomized controlled trials.
- Author
-
Chen, Chen, Wang, Zehua, and Qin, Yan‐Ru
- Subjects
QUALITY of life ,MELANOMA ,IMMUNOTHERAPY - Abstract
Cutaneous melanoma represents around over 90% of all melanoma. With more effective treatments able to extend patients' survival, health‐related quality of life (HRQOL) is increasingly becoming an important endpoint in cancer clinical trials. They are often secondary outcomes measured in phase III randomized controlled trials and their implementation, collection, analysis, and reporting can be challenging methodologically. For these reasons, an increasing number of international recommendations introduced the standards regarding the conduct of HRQOL. In this systematic review, we appraise the adequacy of HRQOL reporting in phase III randomized controlled trials of stage III‐IV cutaneous melanoma and the clinical issues of immunotherapy and small‐molecular‐targeted therapy on HRQOL. Our search strategy totally got 55 articles, and only 13 studies met all inclusion criteria. Findings suggest that most treatments did not yield significant improvements in HRQOL but kept baseline levels, accompanied by prolonged survival and acceptable toxicity. Except for some existing limitations, reporting of HRQOL has made encouraging progress during the period covered by our search, but some aspects still need further optimization. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Identification of PTK6, via RNA Sequencing Analysis, as a Suppressor of Esophageal Squamous Cell Carcinoma
- Author
-
Ma, Stephanie, Bao, Jessie Y.J., Kwan, Pak Shing, Chan, Yuen Piu, Tong, Carol M., Fu, Li, Zhang, Na, Tong, Amy H.Y., Qin, Yan–Ru, Tsao, Sai Wah, Chan, Kwok Wah, Lok, Si, and Guan, Xin–Yuan
- Published
- 2012
- Full Text
- View/download PDF
11. PSCA acts as a tumor suppressor by facilitating the nuclear translocation of RB1CC1 in esophageal squamous cell carcinoma
- Author
-
Zhang, Li-Yi, Wu, Jian-Lin, Qiu, Hai-Bo, Dong, Sui-Sui, Zhu, Ying-Hui, Lee, Victor Ho-Fun, Qin, Yan-Ru, Li, Yan, Chen, Juan, Liu, Hai-Bo, Bi, Jiong, Ma, Stephanie, Guan, Xin-Yuan, and Fu, Li
- Published
- 2016
- Full Text
- View/download PDF
12. Three adiponectin rs1501299G/T, rs822395A/C, and rs822396A/G polymorphisms and risk of cancer development: a meta-analysis
- Author
-
Fan, Hui-Jie, Wen, Zheng-Fang, Xu, Ben-Ling, Wu, Jing-Jing, Jia, Yong-Xu, Gao, Ming, Li, Ming-Jun, and Qin, Yan-Ru
- Published
- 2013
- Full Text
- View/download PDF
13. ADAR1: a promising new biomarker for esophageal squamous cell carcinoma?
- Author
-
Qiao, Jun-Jing, Chan, Tim Hon Man, Qin, Yan-Ru, and Chen, Leilei
- Published
- 2014
- Full Text
- View/download PDF
14. Downregulation of LGI1 promotes tumor metastasis in esophageal squamous cell carcinoma
- Author
-
Zhu, Ying-Hui, Liu, Haibo, Zhang, Li-Yi, Zeng, Tingting, Song, Ye, Qin, Yan-Ru, Li, Lei, Liu, Lulu, Li, Jianbiao, Zhang, Baozhu, and Guan, Xin-Yuan
- Published
- 2014
- Full Text
- View/download PDF
15. XELOX doublet regimen versus EOX triplet regimen as first‐line treatment for advanced gastric cancer: An open‐labeled, multicenter, randomized, prospective phase III trial (EXELOX).
- Author
-
Zhu, Xiao‐Dong, Huang, Ming‐Zhu, Wang, Yu‐Sheng, Feng, Wan‐Jing, Chen, Zhi‐Yu, He, Yi‐Fu, Zhang, Xiao‐Wei, Liu, Xin, Wang, Chen‐Chen, Zhang, Wen, Ying, Jie‐Er, Wu, Jun, Yang, Lei, Qin, Yan‐Ru, Luo, Jian‐Feng, Zhao, Xiao‐Ying, Li, Wen‐Hua, Zhang, Zhe, Qiu, Li‐Xin, and Geng, Qi‐Rong
- Published
- 2022
- Full Text
- View/download PDF
16. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor
- Author
-
Kong, Kar Lok, Kwong, Dora Lai Wan, Chan, Tim Hon-Man, Law, Simon Ying-Kit, Chen, Leilei, Li, Yan, Qin, Yan-Ru, and Guan, Xin-Yuan
- Published
- 2012
- Full Text
- View/download PDF
17. Identification of alpha-actinin 4 and 67 kDa laminin receptor as stage-specific markers in esophageal cancer via proteomic approaches
- Author
-
Fu, Li, Qin, Yan Ru, Xie, Dan, Chow, Hoi Yee, Ngai, Sai Ming, Kwong, Dora L. W., Li, Yan, and Guan, Xin Yuan
- Published
- 2007
- Full Text
- View/download PDF
18. Overexpression of GPR39 contributes to malignant development of human esophageal squamous cell carcinoma
- Author
-
Tang Hong, Nie Changjun, Chen Leilei, Zeng Tingting, Dai Yongdong, Qin Yan-Ru, Zhu Ying-Hui, Liu Haibo, Xie Fajun, Li Yan, Fu Li, and Guan Xin-Yuan
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background By using cDNA microarray analysis, we identified a G protein-coupled receptor, GPR39, that is significantly up-regulated in ESCC. The aim of this study is to investigate the role of GPR39 in human esophageal cancer development, and to examine the prevalence and clinical significance of GPR39 overexpression in ESCC. Methods The mRNA expression level of GPR39 was analyzed in 9 ESCC cell lines and 50 primary ESCC tumors using semi-quantitative RT-PCR. Immunohistochemistry was used to assess GPR39 protein expression in tissue arrays containing 300 primary ESCC cases. In vitro and in vivo studies were done to elucidate the tumorigenic role of GPR39 in ESCC cells. Results We found that GPR39 was frequently overexpressed in primary ESCCs in both mRNA level (27/50, 54%) and protein level (121/207, 58.5%), which was significantly associated with the lymph node metastasis and advanced TNM stage (P < 0.01). Functional studies showed that GPR39 has a strong tumorigenic ability. Introduction of GPR39 gene into ESCC cell line KYSE30 could promote cell proliferation, increase foci formation, colony formation in soft agar, and tumor formation in nude mice. The mechanism by which amplified GPR39 induces tumorigenesis was associated with its role in promoting G1/S transition via up-regulation of cyclin D1 and CDK6. Further study found GPR39 could enhance cell motility and invasiveness by inducing EMT and remodeling cytoskeleton. Moreover, depletion of endogenous GPR39 by siRNA could effectively decrease the oncogenicity of ESCC cells. Conclusions The present study suggests that GPR39 plays an important tumorigenic role in the development and progression of ESCC.
- Published
- 2011
- Full Text
- View/download PDF
19. Down-Regulation of CIDEA Promoted Tumor Growth and Contributed to Cisplatin Resistance by Regulating the JNK-p21/Bad Signaling Pathways in Esophageal Squamous Cell Carcinoma.
- Author
-
Gao, Ya-Ping, Li, Lei, Yan, Jie, Hou, Xiao-Xia, Jia, Yong-Xu, Chang, Zhi-Wei, Guan, Xin-Yuan, and Qin, Yan-Ru
- Subjects
SQUAMOUS cell carcinoma ,TUMOR growth ,CISPLATIN ,GALLBLADDER cancer ,TUMOR suppressor genes ,DNA replication - Abstract
Esophageal squamous cell carcinoma (ESCC) is one of the most common malignancies with poor prognosis and lack of effective targeted therapies. In this study, we investigated the tumor suppressive role of the cell death inducing DFF like effector A (CIDEA) in ESCC. Firstly, public datasets and ESCC tissue microarray analysis showed that CIDEA was frequently down-regulated at both the mRNA and protein level. This was significantly associated with low differentiation and TNM stage in ESCC, and indicated poor prognosis for ESCC patients. Bisulfite genomic sequencing (BGS) and methylation-specific PCR (MSP) analysis revealed that the down-regulation of CIDEA was associated with hypermethylation of its promoter, which was also correlated with the poor prognosis in ESCC patients. In vitro and in vivo functional studies demonstrated that CIDEA decreased cell growth, foci formation, DNA replication, and tumorigenesis in nude mice. Further study revealed that, during starvation or cisplatin induced DNA damage, CIDEA facilitated the G1-phase arrest or caspase-dependent mitochondrial apoptosis through the JNK-p21/Bad pathway. Therefore, CIDEA is a novel tumor suppressor gene that plays an important role in the development and progression of ESCC, and may provide a potential therapeutic target for patients with ESCC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. Direct Targeting of CREB1 with Imperatorin Inhibits TGFβ2‐ERK Signaling to Suppress Esophageal Cancer Metastasis.
- Author
-
Xu, Wen Wen, Huang, Zhi‐Hao, Liao, Long, Zhang, Qi‐Hua, Li, Jun‐Qi, Zheng, Can‐Can, He, Yan, Luo, Ting‐Ting, Wang, Yang, Hu, Hui‐Fang, Zuo, Qian, Chen, Wen‐You, Yang, Qing‐Sheng, Zhao, Jian‐Fu, Qin, Yan‐Ru, Xu, Li‐Yan, Li, En‐Min, Liao, Hua‐Xin, Li, Bin, and He, Qing‐Yu
- Subjects
METASTASIS ,ESOPHAGEAL cancer ,SQUAMOUS cell carcinoma ,EXTRACELLULAR signal-regulated kinases - Abstract
Metastasis accounts for 90% of cancer death worldwide, and effective therapeutic strategies are lacking. The aim of this work is to identify the key drivers in tumor metastasis and screen therapeutics for treatment of esophageal squamous cell carcinoma (ESCC). Gene Ontology analysis of The Cancer Genome Atlas (TCGA) gene expression datasets of ESCC patients with or without lympy metastasis identifies that TGFβ2 is highly enriched in the pathways essential for tumor metastasis and upregulates in the metastatic ESCC tumors. High TGFβ2 expression in ESCC correlates with metastasis and patient survival, and functionally contributes to tumor metastasis via activating extracellular signal‐regulated kinases (ERK) signaling. By screening of a library consisting of 429 bioactive compounds, imperatorin is verified as a novel TGFβ2 inhibitor, with robustly suppressive effect on tumor metastasis in multiple mice models. Mechanistically, direct binding of imperatorin and CREB1 inhibits phosphorylation, nuclear translocation of CREB1, and its interaction with TGFβ2 promoter, represses TGFβ2 expression and fibroblasts‐secreted CCL2, and then inactivates ERK signaling to block cancer invasion and abrogates the paracrine effects of fibroblasts on tumor angiogenesis and metastasis. Overall, the findings suggest the use of TGFβ2 as a diagnostic and prognostic biomarker and therapeutic target in ESCC, and supports the potential of imperatorin as a novel therapeutic strategy for cancer metastasis. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
21. A Predictive Scoring System Based on Inflammatory and Tumor Markers for Gastric Cancer Patients Undergoing Curative Resection.
- Author
-
Feng, Li-Wen, Li, Jing, Liang, Li-Feng, Guo, Qian-Qian, Li, Jiang, Wu, Jian, Zhang, Pei-Hua, and Qin, Yan-Ru
- Subjects
TUMOR markers ,STOMACH cancer ,CANCER patients ,MULTIVARIATE analysis ,PROGRESSION-free survival ,CA 19-9 test - Abstract
Purpose: Inflammation is closely associated with prognosis in gastric cancer (GC). We aimed to assess the predictive value of existing inflammatory and tumor markers in GC, to establish a systemic score based on valuable predictors for early risk stratification of patients, and to create a nomogram for individual risk prediction. Patients and Methods: We retrospectively analyzed 401 GC patients who underwent curative gastrectomy from 2007 to 2016. Results: Through univariate and multivariate survival analysis, age (> 60 years), depth of invasion (pT3– 4), lymph node invasion (pN1– 3), histologic classification (poor), adjuvant chemotherapy (no), albumin fibrinogen ratio (AFR) (< 13.33), and carbohydrate antigen 19-9 (CA19-9) (> 27 U/mL) independently indicated inferior disease-free survival (DFS). In addition, depth of invasion, lymph node invasion, histologic classification, adjuvant chemotherapy, AFR, and CA19-9 were incorporated in the prediction of cancer-specific survival (CSS). A combined AFR and CA19-9 prognostic score (CACPS) was established. Lower AFR (< 13.33) and higher CA19-9 (> 27 U/mL) were allocated 1 point each in the CACPS (range, 0– 2). CACPS can be used as an independent predictor for DFS and CSS in multivariate analysis (for DFS: CACPS 1: HR=2.039, 95% CI: 1.357– 3.065, P=0.001; CACPS 2: HR=2.419, 95% CI: 1.397– 4.186, P=0.002; for CSS: CACPS 1: HR=2.035, 95% CI: 1.292– 3.205, P=0.002; CACPS 2: HR=2.255, 95% CI: 1.252– 4.059, P=0.007), with a higher CACPS indicating poor survival according to Kaplan–Meier curves (both P< 0.001). Moreover, a nomogram for DFS and CSS was generated using the significant characteristics in the multivariate analysis, which exhibited high accuracy (for DFS: C-index=0.743, 95% CI: 0.698– 0.788; for CSS: C-index=0.766, 95% CI: 0.718– 0.814) versus tumor–node–metastasis staging (for DFS: C-index=0.692, 95% CI: 0.650– 0.734; for CSS: C-index=0.720, 95% CI: 0.675– 0.764). Conclusion: Preoperative CACPS exhibited high accuracy in predicting prognosis for GC patients who underwent curative resection. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
22. MicroRNA‐338‐5p reverses chemoresistance and inhibits invasion of esophageal squamous cell carcinoma cells by targeting Id‐1.
- Author
-
Han, Liang, Cui, Di, Li, Bin, Xu, Wen Wen, Lam, Alfred King Y., Chan, Kin Tak, Zhu, Yun, Lee, Nikki P.Y., Law, Simon Y.K., Guan, Xin Yuan, Qin, Yan Ru, Chan, Kwok Wah, Ma, Stephanie, Tsao, Sai Wah, and Cheung, Annie L.M.
- Abstract
5‐Fluorouracil (5‐FU) is a chemotherapeutic agent commonly used to treat esophageal squamous cell carcinoma (ESCC), but acquisition of chemoresistance frequently occurs and the underlying mechanisms are not fully understood. We found that microRNA (miR)‐338‐5p was underexpressed in ESCC cells with acquired 5‐FU chemoresistance. Forced expression of miR‐338‐5p in these cells resulted in downregulation of Id‐1, and restoration of both in vitro and in vivo sensitivity to 5‐FU treatment. The effects were abolished by reexpression of Id‐1. In contrast, miR‐338‐5p knockdown induced 5‐FU resistance in chemosensitive esophageal cell lines, and knockdown of both miR‐338‐5p and Id‐1 resensitized the cells to 5‐FU. In addition, miR‐338‐5p had suppressive effects on migration and invasion of ESCC cells. Luciferase reporter assay confirmed a direct interaction between miR‐338‐5p and the 3′‐UTR of Id‐1. We also found that miR‐338‐5p was significantly downregulated in tumor tissue and serum samples of patients with ESCC. Notably, low serum miR‐338‐5p expression level was associated with poorer survival and poor response to 5‐FU/cisplatin‐based neoadjuvant chemoradiotherapy. In summary, we found that miR‐338‐5p can modulate 5‐FU chemoresistance and inhibit invasion‐related functions in ESCC by negatively regulating Id‐1, and that serum miR‐338‐5p could be a novel noninvasive prognostic and predictive biomarker in ESCC. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
23. Quality of life, effectiveness, and compliance of fruquintinib in the treatment of metastatic colorectal cancer: Results from a prospective real-world study.
- Author
-
Zhang, Jun, Zhang, Hong-Mei, Lin, Ying-Cheng, Cui, Tong-Jian, Wang, Ying, Zhong, Dian-Sheng, Qin, Yan-ru, Zhou, Chan, Li, Jin-Nan, and Zhang, Xue
- Published
- 2023
- Full Text
- View/download PDF
24. First-in-human phase 1 study of pimicotinib (ABSK021), a CSF-1R inhibitor, in patients with advanced solid tumors.
- Author
-
Falchook, Gerald Steven, Liang, Yan, Harvey, R. Donald, Fu, Siqing, Weitao, Yao, Qin, Yan-ru, Zhang, Xiaojing, Henry, Jason Timothy, Zou, Qingping, Shan, Boyao, Liang, Pan, Wang, Chen, Li, Wenjia, Pamuklar, Zehra Nurgul, Pei, Yi, Chang, Zhiwei, Wang, Jiaqiang, Piha-Paul, Sarina A., Bhave, Manali A., and Yin, Yongmei
- Published
- 2023
- Full Text
- View/download PDF
25. Neuropilin-2 promotes tumourigenicity and metastasis in oesophageal squamous cell carcinoma through ERK-MAPK-ETV4-MMP-E-cadherin deregulation.
- Author
-
Fung, Tsun Ming, Ng, Kai Yu, Tong, Man, Chen, Jin‐Na, Chai, Stella, Chan, Kin‐Tak, Law, Simon, Lee, Nikki P, Choi, Mei Yuk, Li, Bin, Cheung, Annie L, Tsao, Sai Wah, Qin, Yan‐Ru, Guan, Xin‐Yuan, Chan, Kwok Wah, and Ma, Stephanie
- Abstract
Oesophageal squamous cell carcinoma ( ESCC) is the most common histological subtype of oesophageal cancer. The disease is particularly prevalent in southern China. The incidence of the disease is on the rise and its overall survival rate remains dismal. Identification and characterization of better molecular markers for early detection and therapeutic targeting are urgently needed. Here, we report levels of transmembrane and soluble neuropilin-2 ( NRP2) to be significantly up-regulated in ESCC, and to correlate positively with advanced tumour stage, lymph node metastasis, less favourable R category and worse overall patient survival. NRP2 up-regulation in ESCC was in part a result of gene amplification at chromosome 2q. NRP2 overexpression promoted clonogenicity, angiogenesis and metastasis in ESCC in vitro, while NRP2 silencing by lentiviral knockdown or neutralizing antibody resulted in a contrary effect. This observation was extended in vivo in animal models of subcutaneous tumourigenicity and tail vein metastasis. Mechanistically, overexpression of NRP2 induced expression of ERK MAP kinase and the transcription factor ETV4, leading to enhanced MMP-2 and MMP-9 activity and, as a consequence, suppression of E-cadherin. In summary, NRP2 promotes tumourigenesis and metastasis in ESCC through deregulation of ERK-MAPK-ETV4-MMP-E-cadherin signalling. NRP2 represents a potential diagnostic or prognostic biomarker and therapeutic target for ESCC. Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
26. Correlations between gastric cancer family history and ROBO2 and RASSF2A gene methylations.
- Author
-
Zhi-Wei Chang, Lei Dong, Yan-Ru Qin, Min Song, Hai-Yun Guo, Qing-Li Zhu, Chang, Zhi-Wei, Dong, Lei, Qin, Yan-Ru, Song, Min, Guo, Hai-Yun, and Zhu, Qing-Li
- Subjects
GASTRIC mucosa ,HISTORY of medicine ,METHYLATION ,POLYMERASE chain reaction ,NEOPLASTIC cell transformation ,CANCER - Abstract
Objective: To explore the correlation between ROBO2 and RASSF2A gene methylations and gastric cancer family history.Materials and Methods: ROBO2 and RASSF2A gene methylations in gastric cancer tissues and peri.cancerous tissues were detected with methylation.specific PCR in 36. patients with gastric cancer family history and 33 without gastric cancer family history. The correlations of ROBO2 and RASSF2A gene methylations with family history, and clinical and pathological characteristics were analyzed.Results: ROBO2 and RASSF2A gene methylations were all significantly higher in gastric cancer tissues (30% and 26%) than in peri-cancerous tissues (0% and 0%) (all P < 0.05). ROBO2 gene methylation was significantly lower in the patients with gastric cancer family history (17%, 6/36) than in the patients without gastric cancer family history (41%, 15/33) (P < 0.05).Conclusion: ROBO2 and RASSF2A gene methylations may be related to gastric tumorigenesis, and ROBO2 gene methylation is associated with sporadic gastric cancer. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
27. High-Dose Aspirin Consumption Contributes to Decreased Risk for Pancreatic Cancer in a Systematic Review and Meta-analysis.
- Author
-
Cui, Xi-Jun, He, Qiang, Zhang, Jian-Min, Fan, Hui-Jie, Wen, Zheng-Fang, and Qin, Yan-Ru
- Published
- 2014
- Full Text
- View/download PDF
28. Cover Image, Volume 42, Issue 4.
- Author
-
Zhu, Xiao‐Dong, Huang, Ming‐Zhu, Wang, Yu‐Sheng, Feng, Wan‐Jing, Chen, Zhi‐Yu, He, Yi‐Fu, Zhang, Xiao‐Wei, Liu, Xin, Wang, Chen‐Chen, Zhang, Wen, Ying, Jie‐Er, Wu, Jun, Yang, Lei, Qin, Yan‐Ru, Luo, Jian‐Feng, Zhao, Xiao‐Ying, Li, Wen‐Hua, Zhang, Zhe, Qiu, Li‐Xin, and Geng, Qi‐Rong
- Published
- 2022
- Full Text
- View/download PDF
29. Single-nucleotide polymorphism-mass array reveals commonly deleted regions at 3p22 and 3p14.2 associate with poor clinical outcome in esophageal squamous cell carcinoma.
- Author
-
Qin, Yan Ru, Fu, Li, Sham, Pak C., Kwong, Dora L.W., Zhu, Cai Lei, Chu, Kevin K.W., Li, Yan, and Guan, Xin-Yuan
- Abstract
Esophageal squamous cell carcinoma (ESCC) is one of the most common solid tumors in the world with poor prognosis. Deletion of chromosome 3p is one of the most frequent chromosomal alterations in ESCC, suggesting the existence of one or more tumor suppressor genes (TSGs) at this region. In the present study, a recently developed high-throughput and high-resolution technology, single-nucleotide polymorphism (SNP)-mass array, was applied to investigate loss of heterozygosity on 3p in 100 primary ESCC cases with 386 SNP markers. Four commonly deleted regions (CDRs) at 3p26.3, 3p22, 3p21.3 and 3p14.2 were identified. Absent and down-regulated expression of several candidate TSGs, including CHL1, PCAF, RBMS3, PLCD1 and CACNA2D3, were detected in primary ESCC tumors and ESCC cell lines. Moreover, deletions of CDRs 2 and 4 were correlated with advanced tumor stage and deletion of CDR2 was associated with tumor metastasis in ESCC. Our findings provided evidence that minimal deleted regions at 3p26.3, 3p22, 3p21.3 and 3p14.2 containing potential TSGs may contribute to the pathogenesis of esophageal cancer. © 2008 Wiley-Liss, Inc. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
30. Integrin α7 is a functional cancer stem cell surface marker in oesophageal squamous cell carcinoma.
- Author
-
Ming, Xiao-Yan, Fu, Li, Zhang, Li-Yi, Qin, Yan-Ru, Cao, Ting-Ting, Chan, Kwok Wah, Ma, Stephanie, Xie, Dan, and Guan, Xin-Yuan
- Published
- 2016
- Full Text
- View/download PDF
31. The promoter hypermethylation of SULT2B1 accelerates esophagus tumorigenesis via downregulated PER1.
- Author
-
Li, Zhuo, Li, Meng‐Yan, Wang, Ling‐Ling, Li, Lei, Chen, Qing‐Yun, Zhu, Ying‐Hui, Li, Yan, Qin, Yan‐ru, and Guan, Xin‐Yuan
- Abstract
Background Methods Results Conclusions Esophageal cancer is currently the eighth most common tumor in the world and a leading cause of cancer death. SULT2B1 plays crucial roles in tumorigenesis. The purpose of this study is to explore the role of SULT2B1 in esophageal squamous cell carcinoma (ESCC).The expression of SULT2B1 and its clinicopathological characteristics were evaluated in ESCC cohorts. Bisulfite genomic sequencing and methylation specific PCR were used to detect the promoter hypermethylation of the SULT2B1 gene. The effects of SULT2B1 on the biological characters of ESCC cells were identified on functional assays. Subcutaneous xenograft models revealed the role of SULT2B1 in vivo with tumor growth. RNA‐Seq analysis and qRT‐PCR were performed to recognize the targeted effect of SULT2B1 on PER1.SULT2B1 was not expressed or at a low level in most patients with ESCC or in ESCC cell lines, and this was accompanied by poor clinical prognosis. Furthermore, the downregulation of SULT2B1 occurred in promoter hypermethylation. According to the functional results, overexpression of SULT2B1 could inhibit tumoral proliferation in vitro and retard tumor growth in vivo, whereas SULT2B1 knockdown could accelerate ESCC progression. Mechanistically, SULT2B1 targeted PER1 at the mRNA level during post‐transcriptional regulation. Finally, PER1 was verified as a suppressor and poor‐prognosis factor in ESCC.SULT2B1 loss is a consequence owing to its ability to promote hypermethylation. In addition, it serves as a suppressor and poor‐prognosis factor because of the post‐transcriptional regulation of PER1 in ESCC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
32. Genome-wide CRISPR/Cas9 screening identifies a targetable MEST-PURA interaction in cancer metastasis.
- Author
-
Xu WW, Liao L, Dai W, Zheng CC, Tan XP, He Y, Zhang QH, Huang ZH, Chen WY, Qin YR, Chen KS, He ML, Law S, Lung ML, He QY, and Li B
- Subjects
- Humans, Molecular Docking Simulation, CRISPR-Cas Systems, Early Detection of Cancer, Cell Line, Tumor, Gene Expression Regulation, Neoplastic, Cell Proliferation, Cell Movement genetics, DNA-Binding Proteins genetics, Transcription Factors genetics, Esophageal Squamous Cell Carcinoma pathology, Esophageal Neoplasms genetics, MicroRNAs genetics
- Abstract
Background: Metastasis is one of the most lethal hallmarks of esophageal squamous cell carcinoma (ESCC), yet the mechanisms remain unclear due to a lack of reliable experimental models and systematic identification of key drivers. There is urgent need to develop useful therapies for this lethal disease., Methods: A genome-wide CRISPR/Cas9 screening, in combination with gene profiling of highly invasive and metastatic ESCC sublines, as well as PDX models, was performed to identify key regulators of cancer metastasis. The Gain- and loss-of-function experiments were taken to examine gene function. Protein interactome, RNA-seq, and whole genome methylation sequencing were used to investigate gene regulation and molecular mechanisms. Clinical significance was analyzed in tumor tissue microarray and TCGA databases. Homology modeling, modified ELISA, surface plasmon resonance and functional assays were performed to identify lead compound which targets MEST to suppress cancer metastasis., Findings: High MEST expression was associated with poor patient survival and promoted cancer invasion and metastasis in ESCC. Mechanistically, MEST activates SRCIN1/RASAL1-ERK-snail signaling by interacting with PURA. miR-449a was identified as a direct regulator of MEST, and hypermethylation of its promoter led to MEST upregulation, whereas systemically delivered miR-449a mimic could suppress tumor metastasis without overt toxicity. Furthermore, molecular docking and computational screening in a small-molecule library of 1,500,000 compounds and functional assays showed that G699-0288 targets the MEST-PURA interaction and significantly inhibits cancer metastasis., Interpretation: We identified the MEST-PURA-SRCIN1/RASAL1-ERK-snail signaling cascade as an important mechanism underlying cancer metastasis. Blockade of MEST-PURA interaction has therapeutic potential in management of cancer metastasis., Funding: This work was supported by National Key Research and Development Program of China (2021YFC2501000, 2021YFC2501900, 2017YFA0505100); National Natural Science Foundation of China (31961160727, 82073196, 81973339, 81803551); NSFC/RGC Joint Research Scheme (N_HKU727/19); Natural Science Foundation of Guangdong Province (2021A1515011158, 2021A0505030035); Key Laboratory of Guangdong Higher Education Institutes of China (2021KSYS009)., Competing Interests: Declaration of interests The authors have declared that no conflict of interest exists., (Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
33. Long-term effect of hospital volume on the postoperative prognosis of 158,618 patients with esophageal squamous cell carcinoma in China.
- Author
-
Lei LL, Song X, Zhao XK, Xu RH, Wei MX, Sun L, Wang PP, Yang MM, Hu JF, Zhong K, Han WL, Han XN, Fan ZM, Wang R, Li B, Zhou FY, Wang XZ, Zhang LG, Bao QD, Qin YR, Chang ZW, Ku JW, Yang HJ, Yuan L, Ren JL, Li XM, and Wang LD
- Abstract
Background: The impact of hospital volume on the long-term survival of esophageal squamous cell carcinoma (ESCC) has not been well assessed in China, especially for stage I-III stage ESCC. We performed a large sample size study to assess the relationships between hospital volume and the effectiveness of ESCC treatment and the hospital volume value at the lowest risk of all-cause mortality after esophagectomy in China., Aim: To investigate the prognostic value of hospital volume for assessing postoperative long-term survival of ESCC patients in China., Methods: The date of 158,618 patients with ESCC were collected from a database (1973-2020) established by the State Key Laboratory for Esophageal Cancer Prevention and Treatment, the database includes 500,000 patients with detailed clinical information of pathological diagnosis and staging, treatment approaches and survival follow-up for esophageal and gastric cardia cancers. Intergroup comparisons of patient and treatment characteristics were conducted with the X
2 test and analysis of variance. The Kaplan-Meier method with the log-rank test was used to draw the survival curves for the variables tested. A Multivariate Cox proportional hazards regression model was used to analyze the independent prognostic factors for overall survival. The relationship between hospital volume and all-cause mortality was assessed using restricted cubic splines from Cox proportional hazards models. The primary outcome was all-cause mortality., Results: In both 1973-1996 and 1997-2020, patients with stage I-III stage ESCC who underwent surgery in high volume hospitals had better survival than those who underwent surgery in low volume hospitals (both P<0.05). And high volume hospital was an independent factor for better prognosis in ESCC patients. The relationship between hospital volume and the risk of all-cause mortality was half-U-shaped, but overall, hospital volume was a protective factor for esophageal cancer patients after surgery (HR<1). The concentration of hospital volume associated with the lowest risk of all-cause mortality was 1027 cases/year in the overall enrolled patients., Conclusion: Hospital volume can be used as an indicator to predict the postoperative survival of ESCC patients. Our results suggest that the centralized management of esophageal cancer surgery is meaningful to improve the survival of ESCC patients in China, but the hospital volume should preferably not be higher than 1027 cases/year., Core Tip: Hospital volume is considered to be a prognostic factor for many complex diseases. However, the impact of hospital volume on long-term survival after esophagectomy has not been well evaluated in China. Based on a large sample size of 158,618 ESCC patients in China spanning 47 years (1973-2020), We found that hospital volume can be used as a predictor of postoperative survival in patients with ESCC, and identified hospital volume thresholds with the lowest risk of death from all causes. This may provide an important basis for patients to choose hospitals and have a significant impact on the centralized management of hospital surgery., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Lei, Song, Zhao, Xu, Wei, Sun, Wang, Yang, Hu, Zhong, Han, Han, Fan, Wang, Li, Zhou, Wang, Zhang, Bao, Qin, Chang, Ku, Yang, Yuan, Ren, Li and Wang.)- Published
- 2023
- Full Text
- View/download PDF
34. Discovery of a New CDK4/6 and PI3K/AKT Multiple Kinase Inhibitor Aminoquinol for the Treatment of Hepatocellular Carcinoma.
- Author
-
Xia ZK, Wang W, Qiu JG, Shi XN, Li HJ, Chen R, Ke KB, Dong C, Zhu Y, Wu SG, Zhang RP, Meng ZR, Zhao H, Gu P, Leung KS, Wong MH, Liu XD, Zhou FM, Zhang JY, Yao YT, Wang SJ, Zhang CY, Qin YR, Lin MC, and Jiang BH
- Abstract
Background: Hepatocellular carcinoma (HCC) is a lethal malignancy lacking effective treatment. The Cyclin-dependent kinases 4/6 (CDK4/6) and PI3K/AKT signal pathways play pivotal roles in carcinogenesis and are promising therapeutic targets for HCC. Here we identified a new CDK4/6 and PI3K/AKT multi-kinase inhibitor for the treatment of HCC. Methods: Using a repurposing and ensemble docking methodology, we screened a library of worldwide approved drugs to identify candidate CDK4/6 inhibitors. By MTT, apoptosis, and flow cytometry analysis, we investigated the effects of candidate drug in reducing cell-viability,inducing apoptosis, and causing cell-cycle arrest. The drug combination and thermal proteomic profiling (TPP) method were used to investigate whether the candidate drug produced antagonistic effect. The in vivo anti-cancer effect was performed in BALB/C nude mice subcutaneously xenografted with Huh7 cells. Results: We demonstrated for the first time that the anti-plasmodium drug aminoquinol is a new CDK4/6 and PI3K/AKT inhibitor. Aminoquinol significantly decreased cell viability, induced apoptosis, increased the percentage of cells in G1 phase. Drug combination screening indicated that aminoquinol could produce antagonistic effect with the PI3K inhibitor LY294002. TPP analysis confirmed that aminoquinol significantly stabilized CDK4, CDK6, PI3K and AKT proteins. Finally, in vivo study in Huh7 cells xenografted nude mice demonstrated that aminoquinol exhibited strong anti-tumor activity, comparable to that of the leading cancer drug 5-fluorouracil with the combination treatment showed the highest therapeutic effect. Conclusion: The present study indicates for the first time the discovery of a new CDK4/6 and PI3K/AKT multi-kinase inhibitor aminoquinol. It could be used alone or as a combination therapeutic strategy for the treatment of HCC., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Xia, Wang, Qiu, Shi, Li, Chen, Ke, Dong, Zhu, Wu, Zhang, Meng, Zhao, Gu, Leung, Wong, Liu, Zhou, Zhang, Yao, Wang, Zhang, Qin, Lin and Jiang.)
- Published
- 2021
- Full Text
- View/download PDF
35. Laminin γ2-mediating T cell exclusion attenuates response to anti-PD-1 therapy.
- Author
-
Li L, Wei JR, Dong J, Lin QG, Tang H, Jia YX, Tan W, Chen QY, Zeng TT, Xing S, Qin YR, Zhu YH, Li Y, and Guan XY
- Abstract
PD-1/PD-L1 blockade therapies provide notable clinical benefits for patients with advanced cancers, but the factors influencing the effectiveness of the treatment remain incompletely cataloged. Here, the up-regulation of laminin γ2 (Ln-γ2) predicted the attenuated efficacy of anti-PD-1 drugs and was associated with unfavorable outcomes in patients with lung cancer or esophageal cancer. Furthermore, Ln-γ2 was transcriptionally activated by transforming growth factor-β1 (TGF-β1) secreted from cancer-associated fibroblasts via JNK/AP1 signaling, which blocked T cell infiltration into the tumor nests by altering the expression of T cell receptors. Coadministration of the TGF-β receptor inhibitor galunisertib and chemotherapy drugs provoked vigorous antitumor activity of anti-PD-1 therapy in mouse tumor models. Therefore, Ln-γ2 may represent a useful biomarker to optimize clinical decisions and predict the response of cancer patients to treatment with anti-PD-1 drugs., (Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).)
- Published
- 2021
- Full Text
- View/download PDF
36. Direct Targeting of CREB1 with Imperatorin Inhibits TGF β 2-ERK Signaling to Suppress Esophageal Cancer Metastasis.
- Author
-
Xu WW, Huang ZH, Liao L, Zhang QH, Li JQ, Zheng CC, He Y, Luo TT, Wang Y, Hu HF, Zuo Q, Chen WY, Yang QS, Zhao JF, Qin YR, Xu LY, Li EM, Liao HX, Li B, and He QY
- Abstract
Metastasis accounts for 90% of cancer death worldwide, and effective therapeutic strategies are lacking. The aim of this work is to identify the key drivers in tumor metastasis and screen therapeutics for treatment of esophageal squamous cell carcinoma (ESCC). Gene Ontology analysis of The Cancer Genome Atlas (TCGA) gene expression datasets of ESCC patients with or without lympy metastasis identifies that TGF β 2 is highly enriched in the pathways essential for tumor metastasis and upregulates in the metastatic ESCC tumors. High TGF β 2 expression in ESCC correlates with metastasis and patient survival, and functionally contributes to tumor metastasis via activating extracellular signal-regulated kinases (ERK) signaling. By screening of a library consisting of 429 bioactive compounds, imperatorin is verified as a novel TGF β 2 inhibitor, with robustly suppressive effect on tumor metastasis in multiple mice models. Mechanistically, direct binding of imperatorin and CREB1 inhibits phosphorylation, nuclear translocation of CREB1, and its interaction with TGF β 2 promoter, represses TGF β 2 expression and fibroblasts-secreted CCL2, and then inactivates ERK signaling to block cancer invasion and abrogates the paracrine effects of fibroblasts on tumor angiogenesis and metastasis. Overall, the findings suggest the use of TGF β 2 as a diagnostic and prognostic biomarker and therapeutic target in ESCC, and supports the potential of imperatorin as a novel therapeutic strategy for cancer metastasis., Competing Interests: The authors declare no conflict of interest., (© 2020 The Authors. Published by WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim.)
- Published
- 2020
- Full Text
- View/download PDF
37. Identification of miR-29c and its Target FBXO31 as a Key Regulatory Mechanism in Esophageal Cancer Chemoresistance: Functional Validation and Clinical Significance.
- Author
-
Li B, Hong P, Zheng CC, Dai W, Chen WY, Yang QS, Han L, Tsao SW, Chan KT, Lee NPY, Law S, Xu LY, Li EM, Chan KW, Qin YR, Guan XY, Lung ML, He QY, Xu WW, and Cheung AL
- Subjects
- Gene Expression Profiling, Humans, Models, Theoretical, Tumor Cells, Cultured, Antineoplastic Agents pharmacology, Drug Resistance, Neoplasm, Esophageal Neoplasms pathology, F-Box Proteins metabolism, Fluorouracil pharmacology, MicroRNAs metabolism, Neoplasms, Squamous Cell pathology, Tumor Suppressor Proteins metabolism
- Abstract
Rationale: Dysregulated microRNA (miRNA) expressions in cancer can contribute to chemoresistance. This study aims to identify miRNAs that are associated with fluorouracil (5-FU) chemoresistance in esophageal squamous cell carcinoma (ESCC). The potential of miR-29c as a novel diagnostic, prognostic and treatment-predictive marker in ESCC, and its mechanisms and therapeutic implication in overcoming 5-FU chemoresistance were explored. Methods: The miRNA profiles of an ESCC cell model with acquired chemoresistance to 5-FU were analyzed using a Taqman miRNA microarray to identify novel miRNAs associated with 5-FU chemoresistance. Quantitative real-time PCR was used to determine miR-29c expression in tissue and serum samples of patients. Bioinformatics, gain- and loss-of-function experiments, and luciferase reporter assay were performed to validate F-box only protein 31 (FBXO31) as a direct target of miR-29c, and to identify potential transcription factor binding events that control miR-29c expression. The potential of systemic miR-29c oligonucleotide-based therapy in overcoming 5-FU chemoresistance was evaluated in tumor xenograft model. Results: MiR-29c, under the regulatory control of STAT5A, was frequently downregulated in tumor and serum samples of patients with ESCC, and the expression level was correlated with overall survival. Functional studies showed that miR-29c could override 5-FU chemoresistance in vitro and in vivo by directly interacting with the 3'UTR of FBXO31, leading to repression of FBXO31 expression and downstream activation of p38 MAPK. Systemically administered miR-29c dramatically improved response of 5-FU chemoresistant ESCC xenografts in vivo . Conclusions: MiR-29c modulates chemoresistance by interacting with FBXO31, and is a promising non-invasive biomarker and therapeutic target in ESCC., Competing Interests: Competing Interests: The authors have declared that no competing interest exists.
- Published
- 2019
- Full Text
- View/download PDF
38. Epigenetic alterations of a novel antioxidant gene SLC22A3 predispose susceptible individuals to increased risk of esophageal cancer.
- Author
-
Xiong JX, Wang YS, Sheng J, Xiang D, Huang TX, Tan BB, Zeng CM, Li HH, Yang J, Meltzer SJ, Mori Y, Qin YR, Guan XY, and Fu L
- Subjects
- Adult, Aged, Aged, 80 and over, Blotting, Western, Case-Control Studies, DNA Damage genetics, DNA Methylation genetics, Female, Fluorescent Antibody Technique, Genetic Predisposition to Disease genetics, Heat-Shock Response, Humans, Lentivirus genetics, Male, Middle Aged, Models, Biological, Promoter Regions, Genetic genetics, Reactive Oxygen Species metabolism, Epigenesis, Genetic genetics, Esophageal Neoplasms genetics, Genome-Wide Association Study methods, Organic Cation Transport Proteins genetics
- Abstract
Esophageal squamous cell carcinoma (ESCC) occurs with the highest frequency in China, especially in the high-risk Northern Chinese. Recent studies have reported that SLC22A3 is significantly downregulated in non-tumor (NT) esophageal tissues from familial ESCC patients compared with those from sporadic ESCC. However, the mechanism of how SLC22A3 regulates familial ESCC remains unknown. In this study, post hoc genome-wide association studies (GWAS) in 496 cases with a family history of upper gastrointestinal tract cancers and 1056 controls were performed and the results revealed that SLC22A3 is a novel susceptibility gene for familial ESCC. Reduced expression of SLC22A3 in NT esophageal tissues from familial ESCC patients significantly correlates with its promoter hypermethylation. Moreover, case-control study of Chinese descendants from different risk areas of China revealed that the methylation of the SLC22A3 gene in peripheral blood leukocyte (PBL) DNA samples could be a risk factor for developing ESCC in this high-risk population. Functional studies showed that SLC22A3 is a novel antioxidant gene, and deregulation of SLC22A3 facilitates heat stress-induced oxidative DNA damage and formation of γ-H2AX foci in normal esophageal epithelial cells. Collectively, we show that epigenetic alterations of SLC22A3 predispose susceptible individuals to increased risk of esophageal cancer., Competing Interests: Competing Interests: The authors have declared that no competing interest exists.
- Published
- 2018
- Full Text
- View/download PDF
39. TSPAN15 interacts with BTRC to promote oesophageal squamous cell carcinoma metastasis via activating NF-κB signaling.
- Author
-
Zhang B, Zhang Z, Li L, Qin YR, Liu H, Jiang C, Zeng TT, Li MQ, Xie D, Li Y, Guan XY, and Zhu YH
- Subjects
- Aged, Animals, Carcinoma, Squamous Cell metabolism, Carcinoma, Squamous Cell pathology, Cell Line, Tumor, Chemokine CCL2 genetics, Chemokine CCL2 metabolism, Esophageal Neoplasms metabolism, Esophageal Neoplasms pathology, Esophageal Squamous Cell Carcinoma, Female, Humans, Intercellular Adhesion Molecule-1 genetics, Intercellular Adhesion Molecule-1 metabolism, Lymphatic Metastasis, Male, Matrix Metalloproteinase 9 genetics, Matrix Metalloproteinase 9 metabolism, Mice, Mice, Nude, MicroRNAs genetics, MicroRNAs metabolism, Middle Aged, NF-KappaB Inhibitor alpha genetics, NF-KappaB Inhibitor alpha metabolism, NF-kappa B metabolism, Neoplasm Grading, Neoplasm Staging, Neoplasm Transplantation, RNA, Small Interfering genetics, RNA, Small Interfering metabolism, Signal Transduction, Tetraspanins antagonists & inhibitors, Tetraspanins metabolism, Tumor Necrosis Factor-alpha genetics, Tumor Necrosis Factor-alpha metabolism, Urokinase-Type Plasminogen Activator genetics, Urokinase-Type Plasminogen Activator metabolism, Vascular Cell Adhesion Molecule-1 genetics, Vascular Cell Adhesion Molecule-1 metabolism, beta-Transducin Repeat-Containing Proteins metabolism, Carcinoma, Squamous Cell genetics, Esophageal Neoplasms genetics, Gene Expression Regulation, Neoplastic, NF-kappa B genetics, Tetraspanins genetics, beta-Transducin Repeat-Containing Proteins genetics
- Abstract
Beta-transducin repeat containing E3 ubiquitin protein ligase (BTRC) is crucial for the degradation of IκBα. Our previous transcriptome sequencing analysis revealed that tetraspanin 15 (TSPAN15) was significantly upregulated in clinical oesophageal squamous cell carcinoma (OSCC) tissues. Here, we show that high TSPAN15 expression in OSCC tissues is significantly associated with lymph node and distant metastasis, advanced clinical stage, and poor prognosis. Elevated TSPAN15 expression is, in part, caused by the reduction of miR-339-5p. Functional studies demonstrate that TSPAN15 promotes metastatic capabilities of OSCC cells. We further show that TSPAN15 specifically interacts with BTRC to promote the ubiquitination and proteasomal degradation of p-IκBα, and thereby triggers NF-κB nuclear translocation and subsequent activation of transcription of several metastasis-related genes, including ICAM1, VCAM1, uPA, MMP9, TNFα, and CCL2. Collectively, our findings indicate that TSPAN15 may serve as a new biomarker and/or provide a novel therapeutic target to OSCC patients.
- Published
- 2018
- Full Text
- View/download PDF
40. RHCG Suppresses Tumorigenicity and Metastasis in Esophageal Squamous Cell Carcinoma via Inhibiting NF-κB Signaling and MMP1 Expression.
- Author
-
Ming XY, Zhang X, Cao TT, Zhang LY, Qi JL, Kam NW, Tang XM, Cui YZ, Zhang BZ, Li Y, Qin YR, and Guan XY
- Subjects
- Animals, Carcinoma, Squamous Cell genetics, Cation Transport Proteins genetics, Cell Line, Tumor, DNA Methylation genetics, DNA Methylation physiology, Esophageal Neoplasms genetics, Esophageal Squamous Cell Carcinoma, Female, Gene Expression Regulation, Neoplastic genetics, Gene Expression Regulation, Neoplastic physiology, Humans, Lymphatic Metastasis genetics, Male, Matrix Metalloproteinase 1 genetics, Membrane Glycoproteins genetics, Mice, Mice, Nude, Middle Aged, Promoter Regions, Genetic genetics, Signal Transduction genetics, Signal Transduction physiology, Carcinoma, Squamous Cell metabolism, Cation Transport Proteins metabolism, Esophageal Neoplasms metabolism, Matrix Metalloproteinase 1 metabolism, Membrane Glycoproteins metabolism
- Abstract
Background and Aims: Esophageal squamous cell carcinoma (ESCC), a major histologic subtype of esophageal cancer, is increasing in incidence, but the genetic underpinnings of this disease remain unexplored. The aim of this study is to identify the recurrent genetic changes, elucidate their roles and discover new biomarkers for improving clinical management of ESCC. Methods: Western blotting and immunohistochemistry were performed to detect the expression level of RHCG. Bisulfite genomic sequencing (BGS) and methylation-specific PCR (MSP) were used to study the methylation status in the promoter region of RHCG. The tumor-suppressive effect of RHCG was determined by both in-vitro and in-vivo assays. Affymetrix cDNA microarray was used to identify the underlying molecular mechanism. Results: RHCG was frequently downregulated in ESCCs, which was significantly correlated with poor differentiation ( P = 0.001), invasion ( P = 0.003), lymph node metastasis ( P = 0.038) and poorer prognosis ( P < 0.001). Demethylation treatment and bisulfite genomic sequencing analyses revealed that the downregulation of RHCG in both ESCC cell lines and clinical samples was associated with its promoter hypermethylation. Functional assays demonstrated that RHCG could inhibit clonogenicity, cell motility, tumor formation and metastasis in mice. Further study revealed that RHCG could stabilize IκB by decreasing its phosphorylation, and subsequently inhibit NF-κB/p65 activation by blocking the nuclear translocation of p65, where it acted as a transcription regulator for the upregulation of MMP1 expression. Conclusions: Our results support the notion that RHCG is a novel tumor suppressor gene that plays an important role in the development and progression of ESCC., Competing Interests: Competing Interests: The authors have declared that no competing interest exists.
- Published
- 2018
- Full Text
- View/download PDF
41. FSTL1 Promotes Metastasis and Chemoresistance in Esophageal Squamous Cell Carcinoma through NFκB-BMP Signaling Cross-talk.
- Author
-
Lau MC, Ng KY, Wong TL, Tong M, Lee TK, Ming XY, Law S, Lee NP, Cheung AL, Qin YR, Chan KW, Ning W, Guan XY, and Ma S
- Subjects
- Adult, Aged, Aged, 80 and over, Animals, Blotting, Western, Carcinoma, Squamous Cell genetics, Carcinoma, Squamous Cell pathology, Cell Line, Tumor, Drug Resistance, Neoplasm genetics, Esophageal Neoplasms genetics, Esophageal Neoplasms pathology, Female, Follistatin-Related Proteins genetics, Gene Expression Profiling methods, Gene Expression Regulation, Neoplastic, Humans, Male, Mice, Inbred BALB C, Mice, Nude, Middle Aged, Neoplasm Metastasis, Reverse Transcriptase Polymerase Chain Reaction, Signal Transduction genetics, Transplantation, Heterologous, Young Adult, Bone Morphogenetic Proteins metabolism, Carcinoma, Squamous Cell metabolism, Esophageal Neoplasms metabolism, Follistatin-Related Proteins metabolism, NF-kappa B metabolism
- Abstract
Esophageal squamous cell carcinoma (ESCC) has a generally poor prognosis, and molecular markers to improve early detection and predict outcomes are greatly needed. Here, we report that the BMP-binding follistatin-like protein FSTL1 is overexpressed in ESCCs, where it correlates with poor overall survival. Genetic amplification of FSTL1 or chromosome 3q, where it is located, occurred frequently in ESCC, where FSTL1 copy number correlated positively with higher FSTL1 protein expression. Elevating FSTL1 levels by various means was sufficient to drive ESCC cell proliferation, clonogenicity, migration, invasion, self-renewal, and cisplatin resistance in vitro and tumorigenicity and distant metastasis in vivo Conversely, FSTL1 attenuation by shRNA or neutralizing antibody elicited the opposite effects in ESCC cells. mRNA profiling analyses suggested that FSTL1 drives ESCC oncogenesis and metastasis through various pathways, with deregulation of NFκB and BMP signaling figuring prominently. Cross-talk between the NFκB and BMP pathways was evidenced by functional rescue experiments using inhibitors of NFκB and TLR4. Our results establish the significance of FSTL1 in driving oncogenesis and metastasis in ESCC by coordinating NFκB and BMP pathway control, with implications for its potential use as a diagnostic or prognostic biomarker and as a candidate therapeutic target in this disease setting. Cancer Res; 77(21); 5886-99. ©2017 AACR ., (©2017 American Association for Cancer Research.)
- Published
- 2017
- Full Text
- View/download PDF
42. Significance of PI3K/AKT signaling pathway in metastasis of esophageal squamous cell carcinoma and its potential as a target for anti-metastasis therapy.
- Author
-
Li B, Xu WW, Lam AKY, Wang Y, Hu HF, Guan XY, Qin YR, Saremi N, Tsao SW, He QY, and Cheung ALM
- Subjects
- Animals, Apoptosis, Carcinoma, Squamous Cell metabolism, Cell Movement, Cell Proliferation, Esophageal Neoplasms metabolism, Female, Follow-Up Studies, Gene Expression Regulation, Neoplastic, Humans, Lymphatic Metastasis, Mice, Mice, Inbred BALB C, Mice, Nude, Neoplasm Invasiveness, Phosphorylation, Prognosis, Signal Transduction, Tumor Cells, Cultured, Xenograft Model Antitumor Assays, Biomarkers, Tumor metabolism, Carcinoma, Squamous Cell secondary, Esophageal Neoplasms pathology, PTEN Phosphohydrolase metabolism, Phosphatidylinositol 3-Kinases metabolism, Proto-Oncogene Proteins c-akt metabolism
- Abstract
Metastasis is the most lethal hallmark of esophageal squamous cell carcinoma (ESCC). The aim of the study is to identify key signaling pathways that control metastasis in ESCC. Highly invasive ESCC sublines (designated I3 cells) were established through three rounds of selection of cancer cells invading through matrigel-coated chambers. Gene expression profile of one of the I3 sublines was compared with that of its parental cell line using cDNA microarray analysis. Gene ontology and pathway analyses of the differentially expressed genes (both upregulated and downregulated) indicated that genes associated with cellular movement and the AKT pathway were associated with increased cancer cell invasiveness. Western blot analysis confirmed increased phosphorylated AKT (p-AKT), N-cadherin and decreased E-cadherin expression in the I3 cells. Immunohistochemistry was used to evaluate the clinical significance of p-AKT expression in ESCC, and the results showed higher p-AKT nuclear expression in lymph node metastases when compared with primary carcinoma. Inactivation of the PI3K/AKT pathway with specific inhibitors, or with PTEN overexpression, resulted in reversed cadherin switching and inhibited cancer cell motility. Inhibition of the pathway by treatment with wortmannin markedly suppressed experimental metastasis in nude mice. Our data demonstrated the importance of the PI3K/AKT signaling pathway in ESCC metastasis and support PI3K/AKT as a valid therapeutic target in treatment of metastatic ESCC.
- Published
- 2017
- Full Text
- View/download PDF
43. The coexpression and prognostic significance of c-MET, fibroblast growth factor receptor 2, and human epidermal growth factor receptor 2 in resected gastric cancer: a retrospective study.
- Author
-
Jia YX, Li TF, Zhang DD, Fan ZM, Fan HJ, Yan J, Chen LJ, Tang H, Qin YR, and Li XY
- Abstract
Molecular-targeted therapy against tyrosine kinase receptors (RTKs) plays an important role in gastric cancer (GC) treatment. Understanding the correlation between RTK coexpression could better guide clinical drug use. In the present study, the coexpression status of c-MET, fibroblast growth factor receptor 2 (FGFR2), and human epidermal growth factor receptor 2 (HER2) in human GC and their clinical significance in clinical therapy were explored. Immunohistochemical (IHC) staining, quantitative real-time polymerase chain reaction and fluorescent in situ hybridization were performed in 143 cases of GC who had undergone gastrectomy without preoperative chemoradiotherapy. Their association with clinicopathological features and clinical prognosis was analyzed. The frequencies of c-MET, FGFR2, and HER2 overexpression were 47.6% (68/143), 34.3% (49/143), and 10.5% (15/143), respectively. In the RTK coexpression study, 30.1% of patients (43/143) were positive for only one RTK, 25.8% (37/143) were positive for two RTKs, 3.5% (5/143) had triple-positive status, and 40.6% (58/143) had triple-negative status. In survival analysis, the overexpression of c-MET, FGFR2, and HER2 were significantly associated with overall survival (OS) ( P =0.018, 0.004, and 0.049, respectively). In coexpression analysis, patients with triple-positive GC had the poorest OS ( P =0.013). In conclusion, RTK coexpression is significantly associated with poor clinical outcome in GC.
- Published
- 2016
- Full Text
- View/download PDF
44. Correlations between gastric cancer family history and ROBO2 and RASSF2A gene methylations.
- Author
-
Chang ZW, Dong L, Qin YR, Song M, Guo HY, and Zhu QL
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Stomach Neoplasms etiology, Stomach Neoplasms pathology, DNA Methylation, Receptors, Immunologic genetics, Stomach Neoplasms genetics, Tumor Suppressor Proteins genetics
- Abstract
Objective: To explore the correlation between ROBO2 and RASSF2A gene methylations and gastric cancer family history., Materials and Methods: ROBO2 and RASSF2A gene methylations in gastric cancer tissues and peri.cancerous tissues were detected with methylation.specific PCR in 36. patients with gastric cancer family history and 33 without gastric cancer family history. The correlations of ROBO2 and RASSF2A gene methylations with family history, and clinical and pathological characteristics were analyzed., Results: ROBO2 and RASSF2A gene methylations were all significantly higher in gastric cancer tissues (30% and 26%) than in peri-cancerous tissues (0% and 0%) (all P < 0.05). ROBO2 gene methylation was significantly lower in the patients with gastric cancer family history (17%, 6/36) than in the patients without gastric cancer family history (41%, 15/33) (P < 0.05)., Conclusion: ROBO2 and RASSF2A gene methylations may be related to gastric tumorigenesis, and ROBO2 gene methylation is associated with sporadic gastric cancer.
- Published
- 2016
- Full Text
- View/download PDF
45. CD68 and interleukin 13, prospective immune markers for esophageal squamous cell carcinoma prognosis prediction.
- Author
-
Li J, Zhang BZ, Qin YR, Bi J, Liu HB, Li Y, Cai MY, Ma S, Chan KW, Xie D, and Guan XY
- Subjects
- Adult, Aged, Antigens, CD immunology, Antigens, Differentiation, Myelomonocytic immunology, Area Under Curve, Biomarkers, Tumor analysis, Carcinoma, Squamous Cell mortality, Esophageal Neoplasms mortality, Esophageal Squamous Cell Carcinoma, Female, Humans, Interleukin-13 immunology, Kaplan-Meier Estimate, Male, Middle Aged, Prognosis, Proportional Hazards Models, ROC Curve, Sensitivity and Specificity, Antigens, CD metabolism, Antigens, Differentiation, Myelomonocytic metabolism, Carcinoma, Squamous Cell immunology, Carcinoma, Squamous Cell pathology, Esophageal Neoplasms immunology, Esophageal Neoplasms pathology, Interleukin-13 metabolism
- Abstract
Purpose: Oncology immunity was reported to play a key role in cancer development and progression, so we investigated the prediction role of several immune markers in esophageal squamous cell carcinoma (ESCC) patients after operation in this study., Patients and Methods: 66 primary ESCC tumor tissues and four sets of tissue microarrays including 705 primary ESCC tumor tissues from four centers were collected and analyzed. Expressions of several immune markers in ESCC tumor tissue were detected with immunohistochemistry staining. Their distribution densities were analyzed with InForm™ 2.0.1 software. All statistic analyses were performed with SPSS16.0 and Stata version 10.0., Results: Survival analyses assessed by Kaplan-Meier plots and log-rank tests demonstrated that densities of CD68 and interleukin 13 (IL-13) in tumor stroma were positively correlated with the overall survival of ESCC patients after operation (p < 0.01 for CD68, p < 0.001 for IL-13). Further, a model based on tumor stroma densities of CD68 and IL-13 was constructed and it could significantly classify patients with poor or good prognosis. This model could further identify high-risk group and low-risk group at the same Tumor lymph Nodes Metastases (TNM) stage. Lastly, a more accuracy model based on TNM stage, densities of CD68 and IL-13 was constructed to predict the prognosis of ESCC patient after operation., Conclusion: Combining the TNM staging system and densities of CD68 and IL-13 could substantially improve the prognosis prediction accuracy of ESCC patient after operation, which might be an excellent tool for selecting patients for individualized therapy in future.
- Published
- 2016
- Full Text
- View/download PDF
46. Competitive Binding Between Id1 and E2F1 to Cdc20 Regulates E2F1 Degradation and Thymidylate Synthase Expression to Promote Esophageal Cancer Chemoresistance.
- Author
-
Li B, Xu WW, Guan XY, Qin YR, Law S, Lee NP, Chan KT, Tam PY, Li YY, Chan KW, Yuen HF, Tsao SW, He QY, and Cheung AL
- Subjects
- Binding, Competitive drug effects, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell pathology, Cdc20 Proteins genetics, Cdc20 Proteins metabolism, Cell Line, Tumor, Cell Proliferation drug effects, Drug Resistance, Neoplasm genetics, E2F1 Transcription Factor genetics, Esophageal Neoplasms drug therapy, Esophageal Neoplasms pathology, Esophageal Squamous Cell Carcinoma, Fluorouracil administration & dosage, Gene Expression Regulation, Neoplastic drug effects, Humans, Inhibitor of Differentiation Protein 1 genetics, Insulin-Like Growth Factor II genetics, Proteolysis drug effects, Signal Transduction drug effects, Thymidylate Synthase biosynthesis, Carcinoma, Squamous Cell genetics, E2F1 Transcription Factor biosynthesis, Esophageal Neoplasms genetics, Inhibitor of Differentiation Protein 1 biosynthesis, Insulin-Like Growth Factor II biosynthesis
- Abstract
Purpose: Chemoresistance is a major obstacle in cancer therapy. We found that fluorouracil (5-FU)-resistant esophageal squamous cell carcinoma cell lines, established through exposure to increasing concentrations of 5-FU, showed upregulation of Id1, IGF2, and E2F1. We hypothesized that these genes may play an important role in cancer chemoresistance., Experimental Design: In vitro and in vivo functional assays were performed to study the effects of Id1-E2F1-IGF2 signaling in chemoresistance. Quantitative real-time PCR, Western blotting, immunoprecipitation, chromatin immunoprecipitation, and dual-luciferase reporter assays were used to investigate the molecular mechanisms by which Id1 regulates E2F1 and by which E2F1 regulates IGF2. Clinical specimens, tumor tissue microarray, and Gene Expression Omnibus datasets were used to analyze the correlations between gene expressions and the relationships between expression profiles and patient survival outcomes., Results: Id1 conferred 5-FU chemoresistance through E2F1-dependent induction of thymidylate synthase expression in esophageal cancer cells and tumor xenografts. Mechanistically, Id1 protects E2F1 protein from degradation and increases its expression by binding competitively to Cdc20, whereas E2F1 mediates Id1-induced upregulation of IGF2 by binding directly to the IGF2 promoter and activating its transcription. The expression level of E2F1 was positively correlated with that of Id1 and IGF2 in human cancers. More importantly, concurrent high expression of Id1 and IGF2 was associated with unfavorable patient survival in multiple cancer types., Conclusions: Our findings define an intricate E2F1-dependent mechanism by which Id1 increases thymidylate synthase and IGF2 expressions to promote cancer chemoresistance. The Id1-E2F1-IGF2 regulatory axis has important implications for cancer prognosis and treatment., (©2015 American Association for Cancer Research.)
- Published
- 2016
- Full Text
- View/download PDF
47. Role of AMPK signaling in mediating the anticancer effects of silibinin in esophageal squamous cell carcinoma.
- Author
-
Li J, Li B, Xu WW, Chan KW, Guan XY, Qin YR, Lee NP, Chan KT, Law S, Tsao SW, and Cheung AL
- Subjects
- AMP-Activated Protein Kinases metabolism, Animals, Antineoplastic Agents administration & dosage, Antineoplastic Combined Chemotherapy Protocols pharmacology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Apoptosis drug effects, Carcinoma, Squamous Cell pathology, Cell Line, Tumor, Cell Proliferation drug effects, Esophageal Neoplasms pathology, Esophageal Squamous Cell Carcinoma, Fluorouracil pharmacology, Humans, Mice, Mice, Nude, Neoplasm Invasiveness prevention & control, Signal Transduction drug effects, Silybin, Silymarin administration & dosage, Xenograft Model Antitumor Assays, AMP-Activated Protein Kinases drug effects, Antineoplastic Agents pharmacology, Carcinoma, Squamous Cell drug therapy, Esophageal Neoplasms drug therapy, Silymarin pharmacology
- Abstract
Objective: Emerging evidence suggests that activation of adenosine monophosphate-activated protein kinase (AMPK) may suppress cancer growth. Identification of novel AMPK activators is therefore crucial to exploit AMPK as a potential target for cancer prevention and treatment., Research Design and Methods: We determined the expression status and role of AMPK in esophageal squamous cell carcinoma (ESCC) and investigated whether silibinin, a nontoxic natural product, could activate AMPK to inhibit ESCC development., Results: Our results from 49 pairs of human ESCC and normal tissues showed that AMPK was constitutively inactive in the majority (69.4%) of ESCC. We found that silibinin induced apoptosis, and inhibited ESCC cell proliferation in vitro and tumorigenicity in vivo without any adverse effects. Silibinin also markedly suppressed the invasive potential of ESCC cells in vitro and their ability to form lung metastasis in nude mice. The anticancer effects of silibinin were abrogated by the presence of compound C or shRNA against AMPK. More importantly, silibinin enhanced the sensitivity of ESCC cells and tumors to the chemotherapeutic drugs, 5-fluorouracil and cisplatin., Conclusions: This preclinical study supports that AMPK is a valid therapeutic target and suggests that silibinin may be a potentially useful therapeutic agent and chemosensitizer for esophageal cancer.
- Published
- 2016
- Full Text
- View/download PDF
48. Suppression of esophageal tumor growth and chemoresistance by directly targeting the PI3K/AKT pathway.
- Author
-
Li B, Li J, Xu WW, Guan XY, Qin YR, Zhang LY, Law S, Tsao SW, and Cheung AL
- Subjects
- Androstadienes chemistry, Animals, Apoptosis, Cell Line, Tumor, Cell Proliferation, Chromones chemistry, Drug Resistance, Neoplasm, Enzyme Inhibitors chemistry, Female, Fluorouracil chemistry, Humans, Mice, Mice, Nude, Morpholines chemistry, Neoplasm Transplantation, Signal Transduction, Wortmannin, Esophageal Neoplasms drug therapy, Esophageal Neoplasms metabolism, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Phosphatidylinositol 3-Kinases metabolism, Proto-Oncogene Proteins c-akt metabolism
- Abstract
Esophageal cancer is the sixth most common cause of cancer-related deaths worldwide. Novel therapeutic intervention is urgently needed for this deadly disease. The functional role of PI3K/AKT pathway in esophageal cancer is little known. In this study, our results from 49 pairs of human esophageal tumor and normal specimens demonstrated that AKT was constitutively active in the majority (75.5%) of esophageal tumors compared with corresponding normal tissues. Inhibition of the PI3K/AKT pathway with specific inhibitors, wortmannin and LY294002, significantly reduced Bcl-xL expression, induced caspase-3-dependent apoptosis, and repressed cell proliferation and tumor growth in vitro and in vivo without obvious toxic effects. Moreover, significantly higher expression level of p-AKT was observed in fluorouracil (5-FU)-resistant esophageal cancer cells. Inactivation of PI3K/AKT pathway markedly increased the sensitivity and even reversed acquired resistance of esophageal cancer cells to chemotherapeutic drugs in vitro. More importantly, the resistance of tumor xenografts derived from esophageal cancer cells with acquired 5-FU resistance to chemotherapeutic drugs was significantly abrogated by wortmannin treatment in animals. In summary, our data support PI3K/AKT as a valid therapeutic target and strongly suggest that PI3K/AKT inhibitors used in conjunction with conventional chemotherapy may be a potentially useful therapeutic strategy in treating esophageal cancer patients.
- Published
- 2014
- Full Text
- View/download PDF
49. Podoplanin‑positive cancer cells at the edge of esophageal squamous cell carcinomas are involved in invasion.
- Author
-
Li JC, Li Y, Ai JY, Chen K, Zhu YH, Fu L, Qin YR, Wang LJ, and Guan XY
- Subjects
- Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Case-Control Studies, Cell Line, Tumor, Cell Proliferation, Esophageal Squamous Cell Carcinoma, Humans, Immunohistochemistry, Membrane Glycoproteins genetics, Middle Aged, Prognosis, RNA, Small Interfering, Transfection, Carcinoma, Squamous Cell diagnosis, Carcinoma, Squamous Cell genetics, Esophageal Neoplasms diagnosis, Esophageal Neoplasms genetics, Gene Expression Regulation, Neoplastic, Membrane Glycoproteins metabolism, Neoplasm Invasiveness diagnosis, Neoplasm Invasiveness genetics
- Abstract
Podoplanin (PDPN) is a well established lymphatic endothelial marker and has frequently been observed in cancer cells at the edge of cancer masses. Previous studies investigating the association between PDPN expression and patient prognosis have had contradictory results. In the present study, it was hypothesized that the different locations of PDPN‑positive cells may explain these varying results. The present study aimed to focus on PDPN expression at the edge of esophageal cancer cell nests. In order to analyze the clinical significance of this PDPN expression, immunohistochemistry was performed using esophageal cancer tissue microarrays. PDPN expression at the edge of the cancer cell nest was found to be significantly associated with invasion (P<0.05) and poor prognosis (P<0.001) in patients with cancer. To further investigate the role of PDPN expression in cancer cells, the PDPN gene was cloned and transfected into esophageal squamous cell carcinoma (ESCC) cell lines. PDPN expression was also knocked down using small interfering RNA. PDPN‑positive cancer cells were found to exhibit invasion characteristics. Thus, PDPN expression at the edge of a cancer cell nest may indicate invasion and represent a poor prognostic factor for ESCCs.
- Published
- 2014
- Full Text
- View/download PDF
50. Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma.
- Author
-
Qin YR, Qiao JJ, Chan TH, Zhu YH, Li FF, Liu H, Fei J, Li Y, Guan XY, and Chen L
- Subjects
- Adenosine Deaminase genetics, Carcinoma, Squamous Cell mortality, Carrier Proteins genetics, Carrier Proteins metabolism, Cell Line, Tumor, Cohort Studies, Disease Progression, Esophageal Neoplasms mortality, Esophageal Squamous Cell Carcinoma, Gene Expression, Gene Expression Regulation, Neoplastic, Humans, Oncogene Proteins genetics, Oncogene Proteins metabolism, RNA-Binding Proteins, Adenosine, Adenosine Deaminase metabolism, Carcinoma, Squamous Cell genetics, Carcinoma, Squamous Cell metabolism, Esophageal Neoplasms genetics, Esophageal Neoplasms metabolism, Inosine, RNA Editing
- Abstract
Esophageal squamous cell carcinoma (ESCC), the major histologic form of esophageal cancer, is a heterogeneous tumor displaying a complex variety of genetic and epigenetic changes. Aberrant RNA editing of adenosine-to-inosine (A-to-I), as it is catalyzed by adenosine deaminases acting on RNA (ADAR), represents a common posttranscriptional modification in certain human diseases. In this study, we investigated the status and role of ADARs and altered A-to-I RNA editing in ESCC tumorigenesis. Among the three ADAR enzymes expressed in human cells, only ADAR1 was overexpressed in primary ESCC tumors. ADAR1 overexpression was due to gene amplification. Patients with ESCC with tumoral overexpression of ADAR1 displayed a poor prognosis. In vitro and in vivo functional assays established that ADAR1 functions as an oncogene during ESCC progression. Differential expression of ADAR1 resulted in altered gene-specific editing activities, as reflected by hyperediting of FLNB and AZIN1 messages in primary ESCC. Notably, the edited form of AZIN1 conferred a gain-of-function phenotype associated with aggressive tumor behavior. Our findings reveal that altered gene-specific A-to-I editing events mediated by ADAR1 drive the development of ESCC, with potential implications in diagnosis, prognosis, and treatment of this disease.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.